PPP lawmakers Kim Hyung-dong and Shin Sung-bum introduced amendments to allow domestic production of CBD and medical cannabis and to exclude CBD from the cannabis definition; a Democratic bill from March 2026 was also pending. The food and drug ministry said it supported a managed domestic supply, but no bill had passed by October 2026. Patients still imported Epidiolex through the orphan-drug centre.[1][2]
Listed for context. No score change is recorded for South Korea here.
References
- 뉴시스 — 의료용 대마 국산화 길 열리나…CBD 생산 허용 법안 발의 (2026. 7. 6.)김형동 의원 대표발의; 원료관리센터archived
- 조선비즈 — [인터뷰] 식약처 마약정책과장 “환자 느는데 의약품 수급 불안, ‘의료용 대마’ 국산화할 때” (2026. 9. 16.)2026년 3월 서미화·김형동 법안, 월 300건 이상 처방, 67% 소아archived
Checked. The date and the event were compared with a source that was read.